Sorfenib For AML Patients With The FLT3-ITD Mutation

Sorfenib slows the spread of cancer cells by inhibiting angiogenesis (VEGFR-2,-3) as well as growth factor receptors (PDGFR, KIT). Recently, it has been used for AML patients with the FLT3-ITD mutation, the most common mutation in AML patients. I like this approach because Sorfenib is a rational designed drug that can not only be used to target specific processes unique to a particular form of cancer (unlike general chemotherapy), but also results in less side effects. The following is a link to a clinical trial using sorafenib.
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant.

 

NEW! AML-MDS POP NOW AVAILABLE FOR DOWNLOAD


Speak Your Mind

*